Frequency of major hemorrhage in patients treated with unfractionated intravenous heparin for deep venous thrombosis or pulmonary embolism: A study in routine clinical practice

Archives of Internal Medicine

Volumn 160, Issue 15, 2000, Pages 2369-2373

  Zidane, Majida ^a   Schram, Miranda T ^a   Planken, Erwin W ^b   Molendijk, Wim H ^c   Rosendaal, Frits R ^a   Van Der Meer, Felix J M ^a   Huisman, Menno V ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Diaconessenhuis Leiden ^*  (Netherlands)

^c RIJNLAND HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

ADULT; AGED; ARTICLE; BLEEDING; CAUSE OF DEATH; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; INCIDENCE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT OUTCOME;

EID: 0034726389     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.15.2369     Document Type: Article

References (25)

1. Salzman EW, Deykin D, Shapiro RM, et al. Management of heparin therapy. N Engl J Med. 1975;292:1046-1050.
2. Glazier RL, Corwell EB. Randomized prospective trial of continuous versus intermittent heparin therapy. JAMA. 1976;236:1365-1367.
3. Mant MJ, O'Brien BD, Thong KL, et al. Haemorrhagic complications of heparin therapy. Lancet. 1977;1:1133-1135.
4. Wilson JR, Lampman J. Heparin therapy: a randomized prospective study. Am Heart J. 1979;97:155-158.
5. Fagher B, Lundh B. Heparin treatment of deep vein thrombosis. Acta Med Scand. 1981;210:357-361.
6. Wilson JE, Bynum LJ, Parkey RW. Heparin therapy in venous thromboembolism. Am J Med. 1981;70:808-816.
7. Bentley PG, Kakkar VV, Scully MF, et al. An objective study of alternative methods of heparin administration. Thromb Res. 1980;18:177-187.
8. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986;315:1109-1114.
9. Doyle DJ, Turpie AG, Hirsh J, et al. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis: a randomized trial. Ann Intern Med. 1987;107:441-445.
10. Walker MG, Shaw JW, Thomson GJ, Cumming JG, Thomas ML. Subcutaneous calcium heparin versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective randomised trial. BMJ. 1987;294:1189-1192.
11. Lopaciuk S, Meissner AJ, Ciesielski L, Korzycki J. Subcutaneous sodium heparin versus intravenous sodium heparin in the treatment of deep vein thrombosis. In: Proceedings of the 6th International Meeting of the Danubian League Against Thrombosis and Haemorrnagic Disorders: May 31 to June 3, 1989; Vienna, Austria.
12. Pini M, Pattacini C, Quintavalla R, et al. Subcutaneous versus intravenous heparin in the treatment of deep venous thrombosis: a randomized controlled trial. Thromb Haemost. 1990;64:222-226.
13. Hommes DW, Bura A, Mazzaloi L, et al. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep venous thrombosis: a meta-analysis. Ann Intern Med. 1992;116:279-284.
14. Levine MN, Raskob GE, Landefeld S, Hirsh J. Hemorrhage complications of anticoagulant treatment. Chest. 1995;108:277-290.
15. Leizorovicz A. Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis: an updated meta-analysis. Drugs. 1996;52(suppl 7):31-37.
16. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334: 677-681.
17. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996;334:682-687.
18. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med. 1997:337:663-669.
19. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997;337:657-662.
20. de Groot MR, Büller HR, ten Cate JW, van Marwijk Kooy M. Use of a heparin nomogram for treatment of patients with venous thromboembolism in a community hospital. Thromb Haemost. 1998;80:70-73.
21. Levine MN, Raskob, GE, Landefeld S, Kearon C. Hemorraghic complications of anticoagulant treatment. Chest. 1998;114:511S-523S.
22. Hull RD, Raskob GE, Brant FR. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep-vein thrombosis. Arch Intern Med. 1997;157: 2562-2568.
23. Hull RD, Raskob GE, Brant RF, et al. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy: the emerging theme of delayed recurrence. Arch Intern Med. 1997;157:2317-2321.
24. Brandies DPM, Heijboer H, Büller HR. et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N Engl J Med. 1992;327:1485-1489.
25. Graafsma YP, Prins MH, Lensing AWA, de Haan RJ, Huisman MV, Büller HR. Bleeding classification in clinical trials: observer variability and clinical relevance. Thromb Haemost. 1997;78:1189-1192.